



21 APR 2005
PCT/EP 03 / 11649
10/532371

INVESTOR IN PEOPLE

PRIORITY DOCUMENT
SUBMITTED OR TRANSMITTED IN
COMPLIANCE WITH
RULE 17.1(a) OR (b)

REC'D 13 NOV 2003

WIPO

PCT

The Patent Office
Concept House
Cardiff Road
Newport
South Wales
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.


Signed


Andrew Gersey

Dated

10 September 2003

Best Available Copy





1/77

0224678.3

Request for grant of a patent

(See the notes on the back of this form. You can also get an explanatory leaflet from the Patent Office to help you fill in this form)

24OCT02 E758078-2 D01030
P01/7700 0.00-0224678.3
The Patent Office
Cardiff Road
Newport
Gwent NP9 1RH

1. Your reference	MG/PMS/P33131	
2. Patent application number (The Patent Office will fill in his part)	23 OCT 2002	0224678.3
3. Full name, address and postcode of the or of each applicant (underline all surnames) Patents ADP number (if you know it) 00473587003 If the applicant is a corporate body, give the country/state of its incorporation	Glaxo Group Limited Glaxo Wellcome House, Berkeley Avenue, Greenford, Middlesex UB6 0NN, Great Britain United Kingdom	
4. Title of the invention	Novel Compounds	
5. Name of your agent (if you have one) "Address for service" in the United Kingdom to which all correspondence should be sent (including the postcode) Patents ADP number (if you know it) 07960982003	Corporate Intellectual Property GlaxoSmithKline Corporate Intellectual Property (CN9 25.1) 980 Great West Road BRENTFORD Middlesex TW8 9GS	
6. If you are declaring priority from one or more earlier patent applications, give the country and the date of filing of the or each of these earlier applications and (if you know it) the or each application number	Country	Priority application number (if you know it) Date of filing (day / month / year)
7. If this application is divided or otherwise derived from an earlier UK application, give the number and the filing date of the earlier application	Number of earlier application	Date of filing (day / month / year)
8. Is a statement of inventorship and of right to grant of a patent required in support of this request? (Answer yes if: a) any applicant named in part 3 is not an inventor, or b) there is an inventor who is named as an applicant, or c) any named applicant is a corporate body See note (d)		


Novel Compounds

The present invention relates to novel piperidine benzamide derivatives having pharmacological activity, processes for their preparation, to compositions containing them and to their use in the treatment of neurological and psychiatric disorders.

WO 02/76925 (Eli Lilly), WO 00/06254 (Societe Civile Bioprojet) and WO 01/66534 (Abbott Laboratories) describe a series of compounds which are claimed to be histamine H3 antagonists.

The histamine H3 receptor is predominantly expressed in the mammalian central nervous system (CNS), with minimal expression in peripheral tissues except on some sympathetic nerves (Leurs *et al.*, (1998), Trends Pharmacol. Sci. 19, 177-183). Activation of H3 receptors by selective agonists or histamine results in the inhibition of neurotransmitter release from a variety of different nerve populations, including histaminergic and cholinergic neurons (Schlicker *et al.*, (1994), Fundam. Clin. Pharmacol. 8, 128-137). Additionally, *in vitro* and *in vivo* studies have shown that H3 antagonists can facilitate neurotransmitter release in brain areas such as the cerebral cortex and hippocampus, relevant to cognition (Onodera *et al.*, (1998), In: The Histamine H3 receptor, ed Leurs and Timmerman, pp255-267, Elsevier Science B.V.). Moreover, a number of reports in the literature have demonstrated the cognitive enhancing properties of H3 antagonists (e.g. thioperamide, clobenpropit, ciproxifan and GT-2331) in rodent models including the five choice task, object recognition, elevated plus maze, acquisition of novel task and passive avoidance (Giovanni *et al.*, (1999), Behav. Brain Res. 104, 147-155). These data suggest that novel H3 antagonists such as the current series could be useful for the treatment of cognitive impairments in diseases such as Alzheimer's disease and related neurodegenerative disorders.

The present invention provides, in a first aspect, a compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:


R¹ represents C₁₋₆ alkyl, OH, aryl or heterocyclyl, wherein said aryl and heterocyclyl groups may be optionally substituted by halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino, oxo, trifluoromethyl or an aryl group;

m is 0, 1 or 2;

R² represents halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl;

n is 0, 1 or 2;

R³ represents -(CH₂)_q-NR¹¹R¹² or a group of formula (i):



wherein q is 2, 3 or 4;

R¹¹ and R¹² independently represent C₁₋₆ alkyl or together with the nitrogen atom to which they are attached represent an N-linked heterocyclic group optionally substituted by one or two R¹⁷ groups;

R¹³ represents hydrogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-aryl or heterocyclyl;

R¹⁴ and R¹⁷ independently represent halogen, C₁₋₆ alkyl, haloC₁₋₆ alkyl, OH, diC₁₋₆ alkylamino or C₁₋₆ alkoxy;

f and k independently represent 0, 1 or 2;

g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0; or solvates thereof.

Alkyl groups, whether alone or as part of another group, may be straight chain or branched and the groups alkoxy and alkanoyl shall be interpreted similarly. Alkyl moieties are more preferably C₁₋₄ alkyl, eg. methyl or ethyl. The term 'halogen' is used herein to describe, unless otherwise stated, a group selected from fluorine, chlorine, bromine or iodine.

The term "aryl" includes phenyl and naphthyl.

The term "heterocyclyl" is intended to mean a 4-7 membered monocyclic saturated or partially unsaturated aliphatic ring containing 1 to 3 heteroatoms selected from oxygen or nitrogen. Suitable examples of such monocyclic rings include pyrrolidinyl, piperidinyl, piperazinyl, morpholinyl, diazepanyl, azepanyl and dihydroimidazolyl.

When present, R¹ preferably represents aryl (eg. phenyl), C₁₋₆ alkyl (eg. methyl), OH or an optionally substituted heterocyclyl group (eg. dihydroimidazol-2-one substituted by phenyl), more preferably R¹ represents methyl.

Preferably, m represents 2.

Preferably, n represents 0.

Preferably, R³ represents -(CH₂)_q-NR¹¹R¹².

Preferably, q is 3.

Preferably, NR¹¹R¹² represents an N-linked heterocyclic group, more preferably unsubstituted piperidine.

Preferred compounds according to the invention include examples E1-E6 as shown below, or a pharmaceutically acceptable salt thereof.


Compounds of formula (I) may form acid addition salts with acids, such as conventional pharmaceutically acceptable acids, for example maleic, hydrochloric, hydrobromic, phosphoric,

acetic, fumaric, salicylic, sulphate, citric, lactic, mandelic, tartaric and methanesulphonic. Salts, solvates and hydrates of histamine H3 receptor antagonists therefore form an aspect of the invention.


- 5 Certain compounds of formula (I) are capable of existing in stereoisomeric forms. It will be understood that the invention encompasses all geometric and optical isomers of these compounds and the mixtures thereof including racemates. Tautomers also form an aspect of the invention.

10 The present invention also provides a process for the preparation of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which process comprises:

- (a) reacting a compound of formula (II)




with a compound of formula (III)



- 20 or a protected derivative thereof, wherein R^1 , R^2 , R^3 , m and n are as defined above and L is OH or a suitable leaving group (eg. a halogen atom such as chlorine); or

- (b) preparing a compound of formula (I) wherein R^4 represents $-(CH_2)_q-NR^{11}R^{12}$ which comprises reacting a compound of formula (IV)



- 30 wherein R^1 , m , R^2 , n , and q are as defined above and L^1 represents a suitable leaving group such as a halogen atom (eg. bromine) with a compound of formula $HNR^{11}R^{12}$; wherein R^{11} and R^{12} are as defined above; and optionally thereafter

- (c) deprotecting a compound of formula (I) which is protected; and optionally thereafter

(d) interconversion to other compounds of formula (I).

Process (a) typically comprises reaction with the compound of formula (III) optionally in the presence of a suitable base such as triethylamine or a solid supported amine, in a suitable solvent such as dichloromethane. When L represents OH, process (a) typically comprises an initial halogenation reaction of the compound of formula (II) with a suitable halogenating agent (eg. thionyl chloride) prior to reaction with the compound of formula (III) as above.


When L represents OH, process (a) may also typically comprise activation of the compound of formula (II) with a coupling reagent such as dicyclohexylcarbodiimide or solid supported carbodiimide in a suitable solvent such as N,N-dimethylformamide followed by reaction with the compound of formula (III).

Process (b) is typically performed in the presence of a suitable solvent (such as 1-butanol) at an elevated temperature.

In process (c), examples of protecting groups and the means for their removal can be found in T. W. Greene 'Protective Groups in Organic Synthesis' (J. Wiley and Sons, 1991). Suitable amine protecting groups include sulphonyl (e.g. tosyl), acyl (e.g. acetyl, 2',2',2'-trichloroethoxycarbonyl, benzyloxycarbonyl or t-butoxycarbonyl) and arylalkyl (e.g. benzyl), which may be removed by hydrolysis (e.g. using an acid such as hydrochloric acid) or reductively (e.g. hydrogenolysis of a benzyl group or reductive removal of a 2',2',2'-trichloroethoxycarbonyl group using zinc in acetic acid) as appropriate. Other suitable amine protecting groups include trifluoroacetyl.(-COCF₃) which may be removed by base catalysed hydrolysis or a solid phase resin bound benzyl group, such as a Merrifield resin bound 2,6-dimethoxybenzyl group (Ellman linker), which may be removed by acid catalysed hydrolysis, for example with trifluoroacetic acid.

Process (d) may be performed using conventional interconversion procedures such as epimerisation, oxidation, reduction, alkylation, nucleophilic or electrophilic aromatic substitution, ester hydrolysis or amide bond formation.

Compounds of formula (II) wherein R³ represents -(CH₂)_q-NR¹¹R¹² may be prepared in accordance with the following procedure:




wherein R^2 , n , q , R^{11} and R^{12} are as defined above, P^1 represents a protecting group such as methyl, ethyl or t-butyl, L^1 and L^2 independently represent a leaving group such as halogen (eg. L^1 represents chlorine and L^2 represents bromine). The $-\text{CO}_2\text{H}$ group of compounds of formula (II)^a may be converted to $-\text{COL}$ wherein L represents a leaving group by, for example, halogenation using thionyl chloride.

Step (i) typically comprises reaction of a compound of formula (V) with a suitable alkylating agent such as 1-bromo-3-chloropropane in a suitable solvent such as acetone in the presence of potassium carbonate.

Step (ii) typically comprises treatment of a compound of formula (VI) with an amine of formula $\text{HNR}^{11}\text{R}^{12}$.

Step (iii) comprises a deprotection reaction which may be performed for example under acidic conditions with hydrochloric acid.

Compounds of formula (II) wherein R^3 represents $-(\text{CH}_2)_q-\text{NR}^{11}\text{R}^{12}$ may also be prepared in accordance with the following procedure:



wherein R^2 , n , q , R^{11} and R^{12} are as defined above.

Step (i) typically comprises reaction of a compound of formula (VIII) in the presence of a suitable base such as sodium hydride in an appropriate solvent such as dimethylsulfoxide or N,N -dimethylformamide.

Step (ii) typically comprises a hydrolysis reaction for example under acidic conditions using hydrochloric acid.

Compounds of formula (IV) may be prepared using an analogous procedure using $\text{HO}-(\text{CH}_2)_q\text{-L}^2$, wherein q is as defined above and L^2 represents an OH group or a group convertible to a leaving group.

Compounds of formula (II) wherein R^3 represents a group of formula (i) may be prepared in a similar manner to the procedure shown above.

Compounds of formula (III) are either commercially available or may be prepared via standard routes, for example, imidazolones (e.g. piperidin-4-yl-4-phenyl-1,3-dihydroimidazol-2-one) may be prepared using the procedures described by Carling *et al.*, *J. Med. Chem.*, 1999, 42, 2706.

Compounds of formula (V) and (VIII) are either known in the literature or can be prepared by analogous methods.

Compounds of formula (I) and their pharmaceutically acceptable salts have affinity for the histamine H3 receptor and are believed to be of potential use in the treatment of neurological diseases including Alzheimer's disease, dementia, age-related memory dysfunction, mild cognitive impairment, cognitive dysfunction, epilepsy, neuropathic pain, inflammatory pain, Parkinson's disease, multiple sclerosis, stroke and sleep disorders including narcolepsy;

psychiatric disorders including schizophrenia, attention deficit hyperactivity disorder, depression and addiction; and other diseases including obesity, asthma, allergic rhinitis, nasal congestion, chronic obstructive pulmonary disease and gastro-intestinal disorders.

- 5 Thus the invention also provides a compound of formula (I) or a pharmaceutically acceptable salt thereof, for use as a therapeutic substance in the treatment or prophylaxis of the above disorders, in particular neurodegenerative disorders including Alzheimer's disease.

- 10 The invention further provides a method of treatment or prophylaxis of the above disorders, in mammals including humans, which comprises administering to the sufferer a therapeutically effective amount of a compound of formula (I) or a pharmaceutically acceptable salt thereof.

- 15 In another aspect, the invention provides the use of a compound of formula (I) or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for use in the treatment of the above disorders.

When used in therapy, the compounds of formula (I) are usually formulated in a standard pharmaceutical composition. Such compositions can be prepared using standard procedures.

- 20 Thus, the present invention further provides a pharmaceutical composition for use in the treatment of the above disorders which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

- 25 The present invention further provides a pharmaceutical composition which comprises the compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

- 30 A pharmaceutical composition of the invention, which may be prepared by admixture, suitably at ambient temperature and atmospheric pressure, is usually adapted for oral, parenteral or rectal administration and, as such, may be in the form of tablets, capsules, oral liquid preparations, powders, granules, lozenges, reconstitutable powders, injectable or infusible solutions or suspensions or suppositories. Orally administrable compositions are generally preferred.

- 35 Tablets and capsules for oral administration may be in unit dose form, and may contain conventional excipients, such as binding agents, fillers, tableting lubricants, disintegrants and acceptable wetting agents. The tablets may be coated according to methods well known in normal pharmaceutical practice.

- 40 Oral liquid preparations may be in the form of, for example, aqueous or oily suspension, solutions, emulsions, syrups or elixirs, or may be in the form of a dry product for reconstitution with water or other suitable vehicle before use. Such liquid preparations may contain conventional additives such as suspending agents, emulsifying agents, non-aqueous vehicles

(which may include edible oils), preservatives, and, if desired, conventional flavourings or colorants.

For parenteral administration, fluid unit dosage forms are prepared utilising a compound of the invention or pharmaceutically acceptable salt thereof and a sterile vehicle. The compound, depending on the vehicle and concentration used, can be either suspended or dissolved in the vehicle. In preparing solutions, the compound can be dissolved for injection and filter sterilised before filling into a suitable vial or ampoule and sealing. Advantageously, adjuvants such as a local anaesthetic, preservatives and buffering agents are dissolved in the vehicle. To enhance the stability, the composition can be frozen after filling into the vial and the water removed under vacuum. Parenteral suspensions are prepared in substantially the same manner, except that the compound is suspended in the vehicle instead of being dissolved, and sterilisation cannot be accomplished by filtration. The compound can be sterilised by exposure to ethylene oxide before suspension in a sterile vehicle. Advantageously, a surfactant or wetting agent is included in the composition to facilitate uniform distribution of the compound.

The composition may contain from 0.1% to 99% by weight, preferably from 10 to 60% by weight, of the active material, depending on the method of administration. The dose of the compound used in the treatment of the aforementioned disorders will vary in the usual way with the seriousness of the disorders, the weight of the sufferer, and other similar factors. However, as a general guide suitable unit doses may be 0.05 to 1000 mg, more suitably 1.0 to 200 mg, and such unit doses may be administered more than once a day, for example two or three a day. Such therapy may extend for a number of weeks or months.

The following Descriptions and Examples illustrate the preparation of compounds of the invention.

Description 1

Ethyl 4-(3-Piperidin-1-ylpropoxy)benzoate (D1)

A stirred mixture of ethyl 4-(3-chloropropoxy)benzoate (4.73g) (D.A. Walsh *et al* J. Med. Chem. 1989, 32(1), 105), piperidine (2.9ml), sodium carbonate (3.1g) and potassium iodide (162mg) in 1-butanol (50ml) was heated at 105° C for 16h. The reaction was cooled to rt, diluted with EtOAc (100ml), washed with water (3x50ml), saturated brine (50ml), dried (MgSO₄) and evaporated to give the title compound (D1) (6.88g). MS electrospray (+ion) 292 (MH⁺). ¹H NMR δ (CDCl₃): 7.98 (2H, d, J=8.8Hz), 6.90 (2H, d, J=8.8Hz), 4.34 (2H, q, J=7.5Hz), 4.06 (2H, t, J=6.3Hz), 2.46 (4H, m), 2.00 (2H, m), 1.50 (6H, m), 1.38 (3H, t, J=7.5Hz).

Description 2


4-(3-Piperidin-1-ylpropoxy)benzoic acid hydrochloride (D2)

A solution of ethyl 4-(3-piperidin-1-ylpropoxy)benzoate (D1) (1.4g) in concentrated hydrochloric acid (15ml) was heated under reflux for 1h, cooled and evaporated to give the title compound (D2) (1.02g). MS electrospray (+ion) 264 (MH⁺). ¹H NMR δ (DMSO-d₆): 10.59 (1H, s), 10.25

(1H, s), 7.90 (2H, d, J=9Hz), 7.02 (2H, d, J=9Hz), 4.14 (2H, t, J=6Hz), 3.05-3.52 (4H, m), 2.91 (2H, m), 2.20 (2H, m), 1.25-1.91 (6H, m).

Example 1


5 N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-4-phenylpiperidine hydrochloride (E1)



A solution of 4-(3-piperidin-1-ylpropoxy)benzoic acid hydrochloride (D2)(150mg) in thionyl chloride (2ml) was refluxed for 1h, cooled to rt and evaporated. The acid chloride was re-
 10 evaporated from DCM (2x3ml). The residue was redissolved in DCM (5ml) and triethylamine (0.21ml) and added to a stirred solution of 4-phenylpiperidine (81mg) in DCM (2ml) at rt. The mixture was stirred for 1h and then chromatographed (silica gel, step gradient 4-8% MeOH in DCM). Fractions containing the required product were treated with excess hydrogen chloride (4M solution in dioxan) and then concentrated to yield the title compound (E1) (173mg). MS
 15 electrospray (+ion) 407 (MH⁺). ¹H NMR δ (DMSO-d₆): 10.29 (1H, s), 7.41 (2H, d, J=8.5Hz), 7.28 (5H, m), 6.99 (2H, d, J=8.5Hz), 4.10 (2H, t, J=6.5Hz), 2.70-3.53 (11H, m), 2.24 (2H, m), 1.30-1.85 (10H, m).

Example 2


20 N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]-4-(4-phenyl-1,3-dihydroimidazol-2-one-1-yl)piperidine hydrochloride (E2)



4-(3-Piperidin-1-ylpropoxy)benzoic acid hydrochloride (D2) (49mg) was converted to the title
 25 compound (E2) by reaction with 4-phenyl-1,3-dihydroimidazol-2-one-1-ylpiperidine (Carling *et al.*, J. Med. Chem., 1999, 42, 2706) (40mg) using the method described in Example 1 (E1) (yield = 73mg). MS electrospray (+ion) 490 (MH⁺). ¹H NMR δ (DMSO-d₆): 10.73 (1H, s), 9.58 (1H, s), 6.96-7.55 (10H, m), 4.14 (2H, t, J=6Hz), 3.25-3.77 (9H, m), 2.90 (2H, m), 2.17 (2H, m), 1.13-1.89 (10H, m).

Example 3

30 N-[4-(3-Piperidin-1-ylpropoxy)benzoyl]piperidine hydrochloride (E3)




35 A solution of 4-(3-piperidin-1-ylpropoxy)benzoic acid hydrochloride (D2) (227mg) in DMF at rt was treated with Argonaut PS Carbodiimide resin (778mg, 1.3mmol/g) and stirred for 5min.

Piperidine (0.05ml) was added and the mixture stirred overnight, filtered and evaporated. The residue was partitioned between EtOAc (10ml) and saturated sodium hydrogen carbonate solution (5ml). The organic phase was collected, washed with water (3x), saturated brine, dried (MgSO₄) treated with excess hydrogen chloride (4M in dioxan) and evaporated to yield the title compound (E3) (72mg). MS electrospray (+ion) 331 (MH⁺). ¹H NMR δ (DMSO-d₆): 10.30 (1H, s), 7.33 (2H, d, J=8.8Hz), 6.97 (2H, d, J=8.8Hz), 4.10 (2H, t, J=6Hz), 2.75-3.70 (10H, m), 2.20 (2H, m), 1.25-1.91 (12H, m).

Examples 4-5 (E4-5)


- 10 Examples 4 – 5 were prepared from 4-(3-piperidin-1-ylpropoxy)benzoic acid hydrochloride (D2) and the appropriate amine using the method outlined in Example 1 (E1) and displayed ¹H NMR and mass spectral data that were consistent with structure.



Example No	R ^x	Mass Spectrum (ES ⁺)
E4		345 [M+H] ⁺
E5		359 [M+H] ⁺

Example 6 (E6)

Example 6 was prepared from 4-(3-piperidin-1-ylpropoxy)benzoic acid hydrochloride (D2) and 4-hydroxy-4-phenylpiperidine using the method outlined in Example 1 (E1) with the exception that polymer supported base was employed. ¹H NMR and mass spectral data were consistent with structure.



Example No	R ^x	Mass Spectrum
E6		423 [M+H] ⁺

Abbreviations

Boc tertbutoxycarbonyl
EtOAc ethyl acetate

h	hour
DCM	dichloromethane
MeOH	methanol
rt	room temperature
5 DCC	dicyclohexylcarbodiimide
DMF	dimethylformamide

All publications, including but not limited to patents and patent applications, cited in this specification are herein incorporated by reference as if each individual publication were specifically and individually indicated to be incorporated by reference herein as though fully set forth.

Biological Data

A membrane preparation containing histamine H3 receptors may be prepared in accordance with the following procedures:

(i) Generation of histamine H3 cell line

The histamine H3 cDNA was isolated from its holding vector, pCDNA3.1 TOPO (InVitrogen), by restriction digestion of plasmid DNA with the enzymes BamH1 and Not-1 and ligated into the inducible expression vector pGene (InVitrogen) digested with the same enzymes. The GeneSwitch™ system (a system where in transgene expression is switched off in the absence of an inducer and switched on in the presence of an inducer) was performed as described in US Patent nos: 5,364,791; 5,874,534; and 5,935,934. Ligated DNA was transformed into competent DH5α *E. coli* host bacterial cells and plated onto Luria Broth (LB) agar containing Zeocin™ (an antibiotic which allows the selection of cells expressing the *sh ble* gene which is present on pGene and pSwitch) at 50µg ml⁻¹. Colonies containing the re-ligated plasmid were identified by restriction analysis. DNA for transfection into mammalian cells was prepared from 250ml cultures of the host bacterium containing the pGeneH3 plasmid and isolated using a DNA preparation kit (Qiagen Midi-Prep) as per manufacturers guidelines (Qiagen).

CHO K1 cells previously transfected with the pSwitch regulatory plasmid (InVitrogen) were seeded at 2x10⁶ cells per T75 flask in Complete Medium, containing Hams F12 (GIBCOBRL, Life Technologies) medium supplemented with 10% v/v dialysed foetal bovine serum, L-glutamine, and hygromycin (100µg ml⁻¹), 24 hours prior to use. Plasmid DNA was transfected into the cells using Lipofectamine plus according to the manufacturers guidelines (InVitrogen). 48 hours post transfection cells were placed into complete medium supplemented with 500µg ml⁻¹ Zeocin™.

10-14 days post selection 10nM Mifepristone (InVitrogen), was added to the culture medium to induce the expression of the receptor. 18 hours post induction cells were detached from the flask using ethylenediamine tetra-acetic acid (EDTA; 1:5000; InVitrogen), following several washes with phosphate buffered saline pH 7.4 and resuspended in Sorting Medium containing Minimum Essential Medium (MEM), without phenol red, and supplemented with Earles salts and 3% Foetal Clone II (Hyclone). Approximately 1x 10⁷ cells were examined for receptor expression by staining with a rabbit polyclonal antibody, 4a, raised against the N-terminal domain of the histamine H3 receptor, incubated on ice for 60 minutes, followed by two washes in sorting

medium. Receptor bound antibody was detected by incubation of the cells for 60 minutes on ice with a goat anti rabbit antibody, conjugated with Alexa 488 fluorescence marker (Molecular Probes). Following two further washes with Sorting Medium, cells were filtered through a 50µm Filcon™ (BD Biosciences) and then analysed on a FACS Vantage SE Flow Cytometer fitted with an Automatic Cell Deposition Unit. Control cells were non-induced cells treated in a similar manner. Positively stained cells were sorted as single cells into 96-well plates, containing Complete Medium containing 500µg ml⁻¹ Zeocin™ and allowed to expand before reanalysis for receptor expression via antibody and ligand binding studies. One clone, 3H3, was selected for membrane preparation.

(ii) Membrane preparation from cultured cells

All steps of the protocol are carried out at 4°C and with pre-cooled reagents. The cell pellet is resuspended in 10 volumes of buffer A2 containing 50mM N-2-hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) (pH 7.40) supplemented with 10e-4M leupeptin (acetyl-leucyl-leucyl-arginal; Sigma L2884), 25µg/ml bacitracin (Sigma B0125), 1mM ethylenediamine tetra-acetic acid (EDTA), 1mM phenylmethylsulfonyl fluoride (PMSF) and 2x10e-6M pepstain A (Sigma). The cells are then homogenised by 2 x 15 second bursts in a 1 litre glass Waring blender, followed by centrifugation at 500g for 20 minutes. The supernatant is then spun at 48,000g for 30 minutes. The pellet is resuspended in 4 volumes of buffer A2 by vortexing for 5 seconds, followed by homogenisation in a Dounce homogeniser (10-15 strokes). At this point the preparation is aliquoted into polypropylene tubes and stored at -70°C.

Compounds of the invention may be tested for *in vitro* biological activity in accordance with the following assays:

(I) Histamine H3 binding assay

For each compound being assayed, in a white walled clear bottom 96 well plate, is added:-

(a) 10µl of test compound (or 10µl of iodophenpropit (a known histamine H3 antagonist) at a final concentration of 10mM) diluted to the required concentration in 10% DMSO;

(b) 10µl ¹²⁵I 4-[3-(4-iodophenylmethoxy)propyl]-1H-imidazolium (iodoproxyfan) (Amersham; 1.85MBq/µl or 50µCi/ml; Specific Activity ~2000Ci/mmol) diluted to 200pM in assay buffer (50mM Tris(hydroxymethyl)aminomethane buffer (TRIS) pH 7.4, 0.5mM ethylenediamine tetra-acetic acid (EDTA)) to give 20pM final concentration; and

(c) 80µl bead/membrane mix prepared by suspending Scintillation Proximity Assay (SPA) bead type WGA-PVT at 100mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting in assay buffer to give a final volume of 80µl which contains 7.5µg protein and 0.25mg bead per well – mixture was pre-mixed at room temperature for 60 minutes on a roller.

The plate is shaken for 5 minutes and then allowed to stand at room temperature for 3-4 hours prior to reading in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data was analysed using a 4-parameter logistic equation.

(II) Histamine H3 functional antagonist assay

For each compound being assayed, in a white walled clear bottom 96 well plate, is added:-

(a) 10µl of test compound (or 10µl of guanosine 5'- triphosphate (GTP) (Sigma) as non-specific binding control) diluted to required concentration in assay buffer (20mM N-2-Hydroxyethylpiperazine-N'-2-ethanesulfonic acid (HEPES) + 100mM NaCl + 10mM MgCl₂, pH7.4 NaOH);

(b) 60µl bead/membrane/GDP mix prepared by suspending wheat germ agglutinin-polyvinyltoluene (WGA-PVT) scintillation proximity assay (SPA) beads at 100mg/ml in assay buffer followed by mixing with membrane (prepared in accordance with the methodology described above) and diluting in assay buffer to give a final volume of 60µl which contains 10µg protein and 0.5mg bead per well – mixture is pre-mixed at 4°C for 30 minutes on a roller and just prior to addition to the plate, 10µM final concentration of guanosine 5' diphosphate (GDP) (Sigma; diluted in assay buffer) is added;

The plate is incubated at room temperature to equilibrate antagonist with receptor/beads by shaking for 30 minutes followed by addition of:

(c) 10µl histamine (Tocris) at a final concentration of 0.3µM; and

(d) 20µl guanosine 5' [γ 35-S] thiotriphosphate, triethylamine salt (Amersham; radioactivity concentration = 37kBq/µl or 1mCi/ml; Specific Activity 1160Ci/mmol) diluted to 1.9nM in assay buffer to give 0.38nM final.


The plate is then incubated on a shaker at room temperature for 30 minutes followed by centrifugation for 5 minutes at 1500 rpm. The plate is read between 3 and 6 hours after completion of centrifuge run in a Wallac Microbeta counter on a 1 minute normalised tritium count protocol. Data is analysed using a 4-parameter logistic equation. Basal activity used as minimum i.e. histamine not added to well.

Results

The compounds of Examples E1-E6 were tested in the histamine H3 functional antagonist assay and exhibited pK_b values >7.5.

CLAIMS:

1. A compound of formula (I) or a pharmaceutically acceptable salt thereof:



wherein:


R¹ represents C₁₋₆ alkyl, OH, aryl or heterocyclyl, wherein said aryl and heterocyclyl groups may be optionally substituted by halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino, oxo, trifluoromethyl or an aryl group;

m is 0, 1 or 2;

R² represents halogen, C₁₋₆ alkyl, C₁₋₆ alkoxy, cyano, amino or trifluoromethyl;

n is 0, 1 or 2;

R³ represents -(CH₂)_q-NR¹¹R¹² or a group of formula (i):



wherein q is 2, 3 or 4;

R¹¹ and R¹² independently represent C₁₋₆ alkyl or together with the nitrogen atom to which they are attached represent an N-linked heterocyclic group optionally substituted by one or two R¹⁷ groups;

R¹³ represents hydrogen, C₁₋₆ alkyl, C₃₋₈ cycloalkyl, -C₁₋₆ alkyl-aryl or heterocyclyl;

R¹⁴ and R¹⁷ independently represent halogen, C₁₋₆ alkyl, haloC₁₋₆ alkyl, OH, diC₁₋₆ alkylamino or C₁₋₆ alkoxy;

f and k independently represent 0, 1 or 2;

g is 0, 1 or 2 and h is 0, 1, 2 or 3, such that g and h cannot both be 0;

or solvates thereof.

2. A compound according to claim 1 which is a compound of formula E1-E6 or a pharmaceutically acceptable salt thereof.

3. A compound according to claim 1 or claim 2 for use in therapy.

4. A compound according to claim 1 or claim 2 for use in the treatment of Alzheimer's disease.

P33131

5. A pharmaceutical composition which comprises a compound according to claim 1 or claim 2 and a pharmaceutically acceptable carrier or excipient.

5

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

☒ **BLACK BORDERS**

☒ **IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**

☒ **FADED TEXT OR DRAWING**

☐ **BLURRED OR ILLEGIBLE TEXT OR DRAWING**

☐ **SKEWED/SLANTED IMAGES**

☒ **COLOR OR BLACK AND WHITE PHOTOGRAPHS**

☐ **GRAY SCALE DOCUMENTS**

☐ **LINES OR MARKS ON ORIGINAL DOCUMENT**

☐ **REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**

☐ **OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.